Next-Generation Protection For Cats
A complete portfolio of vaccines that deliver robust efficacy with a proven safety profile
Nobivac NXT® Feline: Designed With Cats In Mind
Featuring the first major advancement in feline vaccine technology in over 20 years
Testimonials
Testimonial Video 01
“Quote from testimonial video”
Testimonial Video 02
“Quote from testimonial video”
Testimonial video 03
“By triggering a robust antibody and cellular immune response without the use of an adjuvant, RNA particle technology offers an innovative way to deliver next-level protection for cats for FeLV.”
Testimonial video 04
“By triggering a robust antibody and cellular immune response without the use of an adjuvant, RNA particle technology offers an innovative way to deliver next-level protection for cats for FeLV.”
Laboratory overdose/repeat-dose studies1
STUDY DESIGN:
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.
Daily monitoring of:
- Local injection sites assessments
- Clinical observation
- Body temperature measurements
Results1
No serious adverse events were observed in any of the studies.
- Pyrexia occurred most often after the first vaccination and was more consistent following overdose administrations, resolving within two days in all studies.
- Local injection site reactions were the most frequent local reaction observed. These were small and short lived after maximum dosing and more frequent and of greater size and duration after administration of an overdose, but generally diffuse, not warm and not painful and without chronic progression.
Field Study
1STUDY DESIGN:
Safety was assessed in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen – 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.
Daily monitoring of:
- Injection sites
- Systemic reactions
- Rectal temperature
Results1
No serious adverse events were observed in any of the studies.
- Vaccination was well tolerated in both adult cats and kittens.
- Rectal temperatures did not show clinically relevant changes.
- No injection site reactions were observed in any animal from the test group following either the first or second vaccination.
One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination.
Laboratory overdose/repeat-dose studies1
STUDY DESIGN:
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.
Daily monitoring of:
- Local injection sites assessments
- Clinical observation
- Body temperature measurements
Results1
No serious adverse events were observed in any of the studies.
- Pyrexia occurred most often after the first vaccination and was more consistent following overdose administrations, resolving within two days in all studies.
- Local injection site reactions were the most frequent local reaction observed. These were small and short lived after maximum dosing and more frequent and of greater size and duration after administration of an overdose, but generally diffuse, not warm and not painful and without chronic progression.
Field study1
STUDY DESIGN:
Safety was assessed in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen – 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.
Daily monitoring of:
- Injection sites
- Systemic reactions
- Rectal temperature
Results1
No serious adverse events were observed in any of the studies.
- Vaccination was well tolerated in both adult cats and kittens.
- Rectal temperatures did not show clinically relevant changes.
- No injection site reactions were observed in any animal from the test group following either the first or second vaccination.
One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination.
Laboratory overdose/repeat-dose studies
STUDY DESIGN:
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.
Daily monitoring of:
- Local injection sites assessments
- Clinical observation
- Body temperature measurements
Results
No serious adverse events were observed in any of the studies.
Pyrexia occurred most often after the first vaccination and was more consistent following overdose administrations, resolving within two days in all studies.
Local injection site reactions were the most frequent local reaction observed. These were small and short lived after maximum dosing and more frequent and of greater size and duration after administration of an overdose, but generally diffuse, not warm and not painful and without chronic progression.
Field study
STUDY DESIGN:
Safety was assessed in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen – 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.
Daily monitoring of:
- Injection sites
- Systemic reactions
- Rectal temperature
Results
No serious adverse events were observed in any of the studies.
Vaccination was well tolerated in both adult cats and kittens.
Rectal temperatures did not show clinically relevant changes.
No injection site reactions were observed in any animal from the test group following either the first or second vaccination.
One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination.
STUDY DESIGN:
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.
Daily monitoring of:
- Local injection sites assessments
- Clinical observation
- Body temperature measurements
Results
No serious adverse events were observed in any of the studies.
- Pyrexia occurred most often after the first vaccination and was more consistent following overdose administrations, resolving within two days in all studies.
- Local injection site reactions were the most frequent local reaction observed. These were small and short lived after maximum dosing and more frequent and of greater size and duration after administration of an overdose, but generally diffuse, not warm and not painful and without chronic progression.